JP2023500337A - 脳がんを治療するための併用療法 - Google Patents

脳がんを治療するための併用療法 Download PDF

Info

Publication number
JP2023500337A
JP2023500337A JP2022525913A JP2022525913A JP2023500337A JP 2023500337 A JP2023500337 A JP 2023500337A JP 2022525913 A JP2022525913 A JP 2022525913A JP 2022525913 A JP2022525913 A JP 2022525913A JP 2023500337 A JP2023500337 A JP 2023500337A
Authority
JP
Japan
Prior art keywords
seq
acid sequence
amino acid
encoded
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022525913A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021092019A5 (https=
JP2023500337A5 (https=
Inventor
ブレッドロー エイミー－リー
ローウィー イスラエル
スコルニック ジェフリー
ヤン チエン
フェラーロ バーナデット
ウォルターズ ジュウェル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2023500337A publication Critical patent/JP2023500337A/ja
Publication of JPWO2021092019A5 publication Critical patent/JPWO2021092019A5/ja
Publication of JP2023500337A5 publication Critical patent/JP2023500337A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001142—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
JP2022525913A 2019-11-04 2020-11-04 脳がんを治療するための併用療法 Pending JP2023500337A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962930417P 2019-11-04 2019-11-04
US62/930,417 2019-11-04
US202062988102P 2020-03-11 2020-03-11
US62/988,102 2020-03-11
US202063018060P 2020-04-30 2020-04-30
US63/018,060 2020-04-30
US202063070987P 2020-08-27 2020-08-27
US63/070,987 2020-08-27
PCT/US2020/058891 WO2021092019A1 (en) 2019-11-04 2020-11-04 Combination therapy to treat brain cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026002786A Division JP2026074006A (ja) 2019-11-04 2026-01-09 脳がんを治療するための併用療法

Publications (3)

Publication Number Publication Date
JP2023500337A true JP2023500337A (ja) 2023-01-05
JPWO2021092019A5 JPWO2021092019A5 (https=) 2023-11-13
JP2023500337A5 JP2023500337A5 (https=) 2023-11-13

Family

ID=75686760

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525913A Pending JP2023500337A (ja) 2019-11-04 2020-11-04 脳がんを治療するための併用療法

Country Status (13)

Country Link
US (1) US20210128710A1 (https=)
EP (1) EP4055033A4 (https=)
JP (1) JP2023500337A (https=)
KR (1) KR20220097928A (https=)
CN (1) CN114901677A (https=)
AU (2) AU2020380288B2 (https=)
BR (1) BR112022008164A2 (https=)
CA (1) CA3156227A1 (https=)
CO (1) CO2022007361A2 (https=)
IL (1) IL292462A (https=)
MX (1) MX2022005345A (https=)
PH (1) PH12022551078A1 (https=)
WO (1) WO2021092019A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023548746A (ja) 2020-10-13 2023-11-21 クリヤ セラピューティクス インコーポレイテッド サイトカインをコードする核酸を送達するためのウイルスベクターコンストラクトおよびがんを処置するためのその使用
CN113447654B (zh) * 2021-07-15 2022-03-22 广州济士源生物技术有限公司 质谱技术检测尿液中psm-e分子水平在制备用于早期诊断前列腺癌产品中的应用
IL310808A (en) * 2021-08-13 2024-04-01 Inovio Pharmaceuticals Inc Combination therapy to treat brain cancer
US11526994B1 (en) * 2021-09-10 2022-12-13 Neosoma, Inc. Labeling, visualization, and volumetric quantification of high-grade brain glioma from MRI images

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017505125A (ja) * 2014-01-23 2017-02-16 リジェネロン・ファーマシューティカルズ・インコーポレ Ｐｄ−１に対するヒト抗体
WO2018064588A2 (en) * 2016-09-30 2018-04-05 Weiner, David Tert immunogenic compositions and methods of treatment using the same
JP2020521471A (ja) * 2017-05-26 2020-07-27 エピセントアールエックス，インコーポレイテッド 導入遺伝子を保持する組換えアデノウイルス

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084364A2 (en) * 2006-01-13 2007-07-26 The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health Improved il-12 for expression in mammalian cells
PT2961831T (pt) * 2013-02-26 2020-10-12 Memorial Sloan Kettering Cancer Center Composições e métodos para imunoterapêutica
KR20190003938A (ko) * 2016-02-25 2019-01-10 셀 메디카 스위처란트 아게 면역치료를 위한 변형된 세포
WO2018027316A1 (en) * 2016-08-09 2018-02-15 Alkayyal Almohanad Oncolytic rhabdovirus expressing il12
EA201990624A1 (ru) * 2017-03-07 2019-09-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Иммуногенные композиции tert и способы лечения с их использованием
US11603407B2 (en) * 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
CN109486828B (zh) * 2018-12-27 2022-05-31 广东暨大基因药物工程研究中心有限公司 一种编码重组人白细胞介素12的基因及其应用
SG11202111262XA (en) * 2019-05-13 2021-11-29 Regeneron Pharma Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
WO2021051065A1 (en) * 2019-09-12 2021-03-18 Inovio Pharmaceuticals, Inc. Tert, wt-1, pmsa immunogenic compositions and methods of treatment using the same
KR20220091576A (ko) * 2019-10-31 2022-06-30 포티 세븐, 인코포레이티드 혈액암의 항-cd47 및 항-cd20 기반 치료

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017505125A (ja) * 2014-01-23 2017-02-16 リジェネロン・ファーマシューティカルズ・インコーポレ Ｐｄ−１に対するヒト抗体
WO2018064588A2 (en) * 2016-09-30 2018-04-05 Weiner, David Tert immunogenic compositions and methods of treatment using the same
JP2020521471A (ja) * 2017-05-26 2020-07-27 エピセントアールエックス，インコーポレイテッド 導入遺伝子を保持する組換えアデノウイルス

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REARDON DAVID ET AL: "Abstract CT114: IN0-5401 and IN0-9012 delivered by electroporation (EP) in combination with cemiplim", CANCER RESEARCH, vol. vol. 79, no. 13_Supplement, JPN6024044622, 1 July 2019 (2019-07-01), pages 114 - 114, ISSN: 0005682783 *

Also Published As

Publication number Publication date
WO2021092019A1 (en) 2021-05-14
IL292462A (en) 2022-06-01
US20210128710A1 (en) 2021-05-06
AU2020380288B2 (en) 2024-02-01
KR20220097928A (ko) 2022-07-08
CA3156227A1 (en) 2021-05-14
EP4055033A1 (en) 2022-09-14
AU2020380288A1 (en) 2022-06-16
PH12022551078A1 (en) 2024-06-19
CO2022007361A2 (es) 2022-06-10
EP4055033A4 (en) 2023-12-06
BR112022008164A2 (pt) 2022-07-12
MX2022005345A (es) 2022-08-11
AU2024202791A1 (en) 2024-05-23
CN114901677A (zh) 2022-08-12

Similar Documents

Publication Publication Date Title
US12180292B2 (en) CD70 binding molecules and methods of use thereof
KR102375327B1 (ko) 관문 분자를 표적으로 하는 dna 단클론성 항체
AU2020380288B2 (en) Combination therapy to treat brain cancer
RS66543B1 (sr) Strategija doziranja koja ublažava sindrom oslobađanja citokina za cd3/cd20 bispecifična antitela
JP7765407B2 (ja) 再発性呼吸器乳頭腫症のためのワクチン及びそれを使用する方法
JP2005527490A (ja) 筋肉内投与のための二重特異性抗体ｄｎａ構築物
US20250352620A1 (en) Combination therapy to treat brain cancer
JP2026074006A (ja) 脳がんを治療するための併用療法
EA049799B1 (ru) Комбинированная терапия для лечения рака мозга
HK40079946A (en) Combination therapy to treat brain cancer
HK40108628A (zh) 用以治疗脑癌的组合疗法
WO2025240287A1 (en) Methods of treating light chain amyloidosis with bispecific bcma x cd3 antibodies
WO2025244973A1 (en) Methods of treating multiple myeloma with bispecific bcma x cd3 antibodies
HK40074543A (en) Cd70 binding molecules and methods of use thereof
CN120239614A (zh) 用于复发性呼吸道乳头状瘤病的疫苗及其使用方法
HK40009043A (zh) 靶向检查点分子的dna单克隆抗体
HK40034677A (en) Cancer vaccines targeting mesothelin and uses thereof
HK40056070B (en) Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
HK40056070A (en) Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
US20120219591A1 (en) Use of vectors expressing intracellular polynucleotide binding proteins as adjuvants

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250502

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260114